Portfolio for IBD & GI Disorders
Crohn's Disease, Microscopic Colitis, Clostridium difficile infections, Irritable Bowel Syndrome
Approved/CommercialActive
Key Facts
Indication
Crohn's Disease, Microscopic Colitis, Clostridium difficile infections, Irritable Bowel Syndrome
Phase
Approved/Commercial
Status
Active
Company
About Tillotts Pharma
Tillotts Pharma is a commercial-stage, privately held specialty pharma company with a deep focus on gastroenterology. As part of the Zeria Group since 2010, it leverages a global partnership network to market its portfolio of small molecule therapeutics, primarily for inflammatory bowel disease (IBD). With over 400 employees, the company is in a growth phase, expanding its geographic reach through strategic partnerships, such as its recent deal for China.
View full company profile